| Bid price | 415.00 | Open price | 0.00 |
|---|---|---|---|
| Ask price | 515.00 | Prev close | 465.00 |
| High price | 0.00 | Spread | 0.00% |
| Low price | 0.00 | Volume | 0 |
Register now for FREE live Galapagos share prices, Galapagos stock quotes, charts, trades and FREE Galapagos company fundamentals, market news and much much more. Why not upgrade to a premium service and get Galapagos Level 2 Data, indepth research tools and investor commentary for Galapagos (GLPG) and other London Stock Exchange equities.
Register now for FREE Galapagos share price charts
| Name | Galapagos | Epic | GLPG |
|---|---|---|---|
| Activites | Reuters | GLPG.L | |
| ISIN | BE0003818359 | Google Finance | LON:GLPG |
| Share Price (p) | 0.00 | Prev. Share Price (p) | 465.00 |
|---|---|---|---|
| Shares in Issue (m) | 0 | Market Cap (£m) | 0 |
| PE Ratio (x) | 0.00 | Div per share (p) | 0.00 |
| Div yield (%) | 0.00 | Div cover (x) | 0.00 |
| EPS (p) | 0.00 | PEG | 0.00 |
Register now for FREE Galapagos company fundamentals
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;} table.hugin { border-color:black;} td.hugin { padding: 3px; border-color:black;} Galapagos NV: business update Mechelen, Belgium; 18 May 2012 - Galapagos NV (Euronext: GLPG) announces today that the operational and...
Galapagos has started its second phase IIa clinical study with GLPG0634, a novel Janus kinase 1 inhibitor being developed to treat multiple autoimmune diseases, such as rheumatoid arthritis (RA). In this clinical study, the efficacy and safety of GLPG0634 will be evaluated for four weeks in...
Story provided by StockMarketWire.com
More Galapagos Company News >>
Register now for FREE Galapagos company news
No Galapagos Share Price Discussions
Register now for FREE Galapagos share price discussions